USFDAJun 15, 2026, 04:32 PM
Obagi Medical Receives FDA Approval for saypha ChIQ Injectable HA Gel
AI Summary
Waldencast plc announced that its Obagi Medical brand received U.S. FDA approval for Obagi® saypha® ChIQ™ injectable hyaluronic acid gel. This approval significantly expands Obagi Medical's injectable portfolio, reinforcing its strategy to become a leader in advanced skincare and medical aesthetics. The product, developed by Croma-Pharma GmbH, is indicated for cheek augmentation and midface contour deficiencies and builds on the successful launch of Obagi® saypha® MagIQ™, which has received strong positive feedback from providers.
Key Highlights
- Obagi Medical received FDA approval for Obagi® saypha® ChIQ™ injectable hyaluronic acid (HA) gel.
- The approval expands Obagi Medical's injectable portfolio and strengthens its position in dermatological aesthetics.
- Obagi® saypha® ChIQ™ is indicated for cheek augmentation and correction of midface contour deficiencies in patients over 21.
- The product was developed by Croma-Pharma GmbH using proprietary MACRO Core Technology.
- This approval follows the successful launch of Obagi® saypha® MagIQ™.
- Interim data from the ALOHA Program shows 94% of injectors believe Obagi® saypha® MagIQ™ complements existing filler options.
- 42.6% of practices using Obagi® saypha® MagIQ™ have evaluated Obagi skincare, significantly above the industry norm of 1 in 10.
- The saypha® line has produced over 130 million syringes globally, setting high standards for safety and quality.
Price Impact
More from WALD